Introduction
, suggesting that the Fusion proteins are commonly the result of chromo-AF4 segment has a role in controlling of the lineage. The somal translocations in leukemias and solid tumors in translocation t(9;11)(p22;q23) is mainly associated with which chromosomal breaks occur within genes on each acute myeloid leukemias and fuses AF9 to MLL (Iida et chromosome (Rabbitts, 1994) . In assessing the relevance of such proteins in tumorigenesis, in vivo experial., 1993; Nakamura et al., 1993) , suggesting a role for mental models are needed that facilitate the study of AF9 in myeloid disease. Nonetheless, the translocations tumor development and progression and overt tumor affecting MLL can occur before lineage commitment outgrowth. Transgenesis is an important method that because different tumor types can carry chromosomes allows various stages of tumor development to be studwith similar breakpoints (Corral et al., 1993; Lo-Coco et ied (Adams and Cory, 1991) . However, it has drawbacks, al., 1993; Thirman et al., 1993) and thus the fusion partprincipally the difficulty of choosing a promoter to enginers may perform different functions. To define the funcneer expression in the appropriate cell type in vivo. Hotion of the fusion proteins, it will be necessary to develop mologous recombination provides an alternative for the a biological model of leukemia associated with MLL manipulation of genes in the mouse genome (Thomas gene fusions and Capecchi, 1987) . In addition to gene targeting to
We have determined the validity of the homologous produce null mutations, this method can be used to recombination strategy by studying the role of the MLLintroduce new genetic information into gene loci, for AF9 fusion in tumorigenesis. Homologous recombinaexample, replacement of En-1 by En-2 sequences to tion in ES cells has been used to create an in-frame rescue the En-1 mutant phenotype (Hanks et al., 1995) fusion of AF9 with exon 8 of mouse Mll. Mutant ES cells or the introduction of the lacZ gene as a fusion within were introduced into blastocysts, which were used to produce chimeric mice. These chimeric mice develop of tumorigenesis mediated via fusion oncogenes.
Results

Homologous Recombination to Produce
Mll-AF9 Fusion The strategy of creating fusion genes by homologous recombination in ES cells was tested by studying the Mll-AF9 fusion in the development of acute leukemia. Three different targeting constructs involving the mouse Mll gene were used (Figure 1) . A targeting vector (designated Mll-AF9; Figure 1A ) was prepared in which the 3Ј-terminal human AF9 sequence was fused within exon 8 of Mll, creating a vector in which the AF9 sequence was fused to Mll at about the position of fusions found after t(9;11)(p22;q23) in one subset of AF9 breakpoints (Iida et al., 1993; Nakamura et al., 1993 ) ( Figure 1C compares the junctional sequences with Mll exon 8 and human AF9 sequences). The targeting clone was made with the simian virus 40 (SV40) poly(A) site downstream of the AF9 translation stop codon. A second targeting vector was prepared with a short peptide epitope (clone designated Mll-myc; Figure 1B ) instead of the AF9 sequences. Both vectors also carried the MC1-neomycin resistance gene (MC1-neo) downstream of the fusion gene to confer resistance to G418 (Figure 1 ) and the herpes simplex virus (HSV) thymidine kinase gene to allow negative selection of nonhomologous integrations (Thomas and Capecchi, 1987; Mansour et al., 1988) . Introduction of these targeting vectors into E14 ES cells allowed selection of clones in which either an AF9 fusion or the peptide fusion had occurred by homologous recombination at the same position in Mll exon 8 ( Figure 1C) . Transcription of the fusion gene occurs from the endogenous Mll promoter, through exon 1 to exon 8 of the gene to include the fused segment. Clones were injected into blastocysts, and chimeric mice were produced with varying degrees of chimerism. Two independent Mll-AF9 ES cell clones and one Mll-myc ES cell clone with normal karyotypes were injected into C57Bl/6 blastocysts.
A third construct was prepared with a fusion involving exon 3 of Mll ( Figures 1D and 1E ). This genomic region ( Figure 2A) , showing that mRNA transcripts are made activity, the distribution of ES-derived cells in hematological tissues. Blue-stained cells were visible in cytofrom the targeted alleles in ES cells. Expression of the AT-lac allele was substantiated by histochemical analyspin preparations of bone marrow, spleen, and thymus cells ( Figure 2C ). In chimeric bone marrow, megakaryosis of ␤-galactosidase protein production. Cytospin preparations were made of Mll-AF9, AT-lac, and Mllcytes, neutrophils, and myelocytes shared nuclear staining, even though the Mll gene is truncated at exon 3. myc targeted ES cells, and each was stained with X-Gal to detect ␤-galactosidase. Blue staining due to This has clear implications for the subcellular location of the MLL fusion proteins after chromosomal transloca-␤-galactosidase enzyme activity was seen in the AT-lac ES cells, but not in the Mll-AF9 or Mll-myc cells (Figure tions, since these fusions include the corresponding region of MLL and therefore may be nuclear proteins. 2B). Hence, the Mll promoter is active in dividing ES cells, and the three targeted Mll alleles are correspondIn addition, both the chimeric spleen and thymus contain blue-stained lymphocytes. Normal mouse bone marrow, ingly expressed in the specific targeted clones.
Cells and in Chimeric Mice
Chimeric mice were generated with AT-lac targeted spleen, and thymus cells treated in parallel did not exhibit any blue-staining cells (data not shown). Thus, tar-ES cells and used to investigate, via ␤-galactosidase geted ES cell derivatives are present in the three major hematological organs in the AT-lac chimeric mice, and Mll expression occurs in the ES cell-derived myeloid (compared with the 13 kb fragment in normal DNA), which was and lymphoid lineage cells in chimeric mice.
detected by the 1.7XhAT13 probe indicated.
(E) The sequence at the junction of Mll exon 3 and the lacZ gene.
The Mll Gene Expression Is Widespread
A previously cloned lacZ cassette with SfiI restriction sites (Dear et
The above evidence suggests a wide distribution of noral., 1995) was used to produce an in-frame fusion between Mll and lacZ genes.
mal Mll expression in mice. The targeted AT-lac ES cells allowed the distribution of Mll promoter activity to be assessed further during embryogenesis and in adult tissue. Germline transmission of the AT-lac allele was obtained from a number of chimeric mice, and the tissue distribution of Mll promoter activity was monitored by the ␤-galactosidase activity. In parallel with recent data obtained with a similar lacZ fusion (Yu et al., 1995) , we observed more or less uniform ␤-galactosidase expression in embryonic day 13.5 (E13.5) and also in E18.5 heterozygous embryos (data not shown). In addition, expression continues into adults, where expression of ␤-galactosidase was found in most tissues (data not shown).
The specific cells that express the Mll-lacZ fusion in the lymphoid organs were assessed by fluorescenceactivated cell sorter (FACS) analysis using a substrate (CMFDG; see Experimental Procedures) that elicits green fluorescence in cells containing ␤-galactosidase activity. The comparison of single cell suspensions from the spleen and thymus of AT-lac carrier mice with those from wild-type mice showed that most of the splenic and thymic lymphocytes from the ϩ/Ϫ, but not the ϩ/ϩ, mice express ␤-galactosidase activity, and therefore the Mll promoter is active ( Figure 3A) .
Since the majority of cells in a normal mouse thymus express the surface markers CD4 and CD8, the CMFDG fluorescence data ( Figure 3A) indicate that the doublepositive CD4 ϩ /CD8 ϩ T cells express the Mll gene. This was confirmed using double fluorescence with CMFDG and antibody binding either CD4 ( Figure 3B ) or CD8 ( Figure 3C ). Approximately 93% of thymus cells from a normal mouse and from an AT-lac ϩ/Ϫ mouse expressed CD4 ( Figure 3B ). The fluorescence profile was shifted to the right owing to the presence of doublefluorescent cells expressing both CD4 and ␤-galactosidase in the AT-lac thymocytes ( Figure 3B ). Doublefluorescent cells, positive for the CD8 marker and ␤-galactosidase activity, were identified by similar analysis ( Figure 3C ). The same proportion of thymocytes expressed the CD8 marker in both ϩ/ϩ and ϩ/Ϫ animals, and double-fluorescent cells were present in the ϩ/Ϫ mouse ( Figure 3C ). Splenic B cells (B220 positive) and T cells (B220 nega- 
Cell-Derived Blood Contribution
Cohorts of chimeric mice were generated by injection any signs of illness were subjected to this analysis (comof each targeted clone into blastocysts to compare the pared with samples prepared from either C57 tissue or effect of the Mll-AF9 fusion gene with the AT-lac and E14 ES cell extract; Figures 4A-4C ). Mll-myc fusions. Peripheral blood samples were taken Nine chimeric mice, about 9 to 10 months old, derived from adult chimeric mice, and the contribution originatby injecting the AT-lac targeted ES cells and with variing from the 129-derived ES cells, injected into the able chimerism based on estimated coat color contribuC57Bl/6 blastocysts, was determined by glucose phostion, were examined. Only two of these chimeras had phate isomerase (GPI) analysis (Papaioannou and Johnson, 1993 ). Blood samples from groups of mice without any significant E14 contribution in blood ( Figure 4A , mice 1040 and 1041), and this did not correlate directly with and F12; Figures 5A-5D) . Furthermore, three different groups of chimeras derived at different times from ES the level of chimerism estimated by coat color. Five cell clone F3 show a high incidence of acute leukemia Mll-myc chimeras were analyzed at 1 year of age, and (groups 1-3 in Figures 5A-5C ). none showed any ES cell blood contribution ( Figure 4B ).
The characteristic pathological features of the disease Conversely, all of the Mll-AF9 mice had a high ES GPI in the chimeras were an enlarged pale spleen, an encontribution by about 6 months of age ( Figure 4C ), irrelarged pale liver with pronounced white spots, and pale spective of coat color. In addition, most of the Mll-AF9 kidneys. The thymi generally appeared normal. The fechimeras analyzed had a significant ES cell-derived murs were macroscopically pale, indicating replaceblood contribution soon after birth (data not shown). ment of normal hematopoietic tissue by leukemic cells. This high blood contribution was observed for targeted GPI analysis of tissue specimens from Mll-AF9 mice, ES cells derived from the E14 clones described here which were sacrificed at the time when symptoms beand for similar Mll-AF9 targeted ES cells made in the gan, suggested the existence of a leukemic condition, CCB line (A. Smith, H. I., and T. H. R., unpublished data).
since bone marrow, spleen, and thymus samples A preferential expansion of ES cell-derived hematopoishowed very high ES cell-derived contribution (Figures etic cells therefore takes place in the Mll-AF9-derived 4F and 4G). An Mll-AF9 chimera M4 (from ES cell clone chimeric mice, but not in AT-lac-or Mll-myc-derived F3) showed approximately similar ES contribution in mice.
blood at two separate times of sampling, while at time of death the bone marrow was essentially all ES-derived cells ( Figure 4F ). Mll-AF9 chimera F1 (from ES clone Mll-AF9 Chimeras Develop Acute Leukemia F12) showed a progressive increase in ES contribution Mll-AF9 chimeric mice began to show signs of distress in blood, and both the bone marrow and thymus com-(from 4 months of age onward) characterized by indolent prised only ES cell derivatives, while the spleen had habit, slow movement, hunched gait, and ruffled hair, around 90% ES cell derivatives at the time of death with more advanced disease associated with respiratory ( Figure 4G ). Contributions of ES-derived cells to other difficulties. Postmortem examination showed consistissues have been tested by GPI analysis in all three tent evidence of hematological disease, which was chartypes of chimeric mice, and all the tissues analyzed acterized as acute leukemia due to hypercellularity, and were found to have ES cell derivatives ( Figures 4D-4G ). blasts accounted for more than 30% of the nucleated However, no tumors of other tissues were found in these bone marrow cells. Only 3 mice out of a total of 35 mice, despite widespread activity of the Mll promoter survived beyond 12 months, and the incidence of leuke- (Figures 2 and 3) . mia was approximately the same in chimeras made from While a high proportion of Mll-AF9 mice developed acute leukemia, no disease appeared in either control two independently targeted clones (Mll-AF9 clones F3 Histograms indicating levels of chimerism (based on coat color) for individual mice and the age (in months) at which leukemia was present are shown for each case of Mll-AF9 chimeras (no disease has been found in any AT-lac or Mll-myc chimeras). Two Mll-AF9 targeted ES clones (F3 and F12) were used to generate chimeric mice (A-D), and clone F3 was used for three separate groups of mice (A-C). One clone of AT-lac and one of Mll-myc were injected into blastocysts, and chimeric mice were obtained. The age at which disease occurred in the Mll-AF9 chimeric mice is indicated.
group of AT-lac or Mll-myc mice at 12 months (Figures blasts with cytoplasmic granules staining with Sudan black B cytochemical stain (the bottom right panel of 5E and 5F). This does not appear simply to reflect the lack of ES cell contribution in these mice, since the level Figure 6A shows a myeloblast whose cytoplasm is stained by Sudan black). of chimerism, evaluated by coat color, was as high as 90% in some mice ( Figure 5 ). Further GPI analysis of Analysis of tissues from a mouse derived from the Mll-AF9 ES clone F12 is shown in Figure 6B (mouse F1). tumors from these mice (examples are shown in Figures  4D and 4E) showed that significant numbers of ES cells Femur sections revealed hypercellularity and homogeneous appearance of leukemic cells. The liver was highly contributed to the peripheral organs.
infiltrated with leukemic cells, and these cells stained using a naphthol AS-D chloroacetate esterase substrate Myeloid Leukemia in the Mll-AF9 Mice Detailed analysis of the leukemic cells in the chimeric (which is reactive with myeloblastic cells; Figure 6B ). The peripheral blood from this mouse contained cells Mll-AF9 mice established the diagnosis as acute myeloid leukemia in those analyzed. All marrow samples with monocytoid appearance (bottom panels of Figure  6B compare blood from F1 with an AT-lac-derived conanalyzed were overtly hypercellular, with a high proportion of blast cells and extramedullary hematopoiesis trol, 1034). This mouse was suffering from an acute myeloid leukemia, and the Mll-AF9 mice develop overt, evident in spleen and liver (particularly spleen). In some mice, circulating red cells containing Howell-Jolly bodacute leukemia of the myeloid type, showing a range of differentiation. We cannot however exclude a possible ies were observed (a feature of functional hyposplenism), and a significant percentage of myeloblasts was mixed lineage involvement. usually evident in the peripheral blood. Some mice exhibited acute leukemia with monocytic differentiation, Discussion while others showed poorly differentiated blasts in marrow and peripheral blood. While an enlarged spleen is Homologous Recombination as a Strategy to Make Fusion Oncogenes a characteristic of either myeloid or lymphoid acute leukemia, clonal B cell lymphoproliferation was excluded
In vivo models of cancer development are needed for a comprehensive understanding of the biology of cancer. by analysis of immunoglobulin gene rearrangement in spleen DNA (data not shown).
Animal models of tumorigenesis offer an ideal means of achieving this. The most often used approach is trans- Figure 6 shows specific analysis of the tumor cells from two Mll-AF9 mice. Histology of liver sections of genesis (Adams and Cory, 1991) . More recently, new technologies based on homologous recombination in mouse M4, compared with a chimeric AT-lac-derived mouse (1034 in Figure 6A ), showed invasion of the M4 ES cells have been used to mimic chromosomal translocations by placing loxP recombination sites on nonholiver by malignant cells, with heavy tumor deposits around the blood vessels. Marrow sections revealed mologous chromosomes and selecting for interchromosomal translocation (Smith et al., 1995;  van Deursen et hypercellularity due to the uniform presence of blast cells, and the fat spaces typical of normal marrow (seen al., 1995) . As an alternative to these approaches, we have used homologous recombination to generate an in 1034 in Figure 6A ) were absent from the femur marrow of mouse M4 ( Figure 6A ). The peripheral blood had in-frame fusion of AF9 with Mll, and we find that this causes tumors in the chimeric mice. This strategy has many circulating myeloblasts, and blood films contained the advantage of using the normal transcriptional control be made from our experiments. First, the Mll-AF9 fusion gene is important for tumor development and, second, elements of Mll to express the Mll-AF9 fusion, much the same as the MLL-AF9 fusion gene would be controlled the phenotype of those tumors is close to the spectrum of tumors seen in patients with translocation t(9;11). after the specific chromosomal translocation.
In view of these data, the role of other MLL gene There was no disease development in either the AT-lac or the Mll-myc chimeric mice, despite the fact that the fusions in tumorigenesis should be readily testable by using a similar strategy to clone MLL fusions with, for site of fusion of the MYC peptide epitope was identical with that of the AF9 fusion. Also, chimeric mice estabexample, AF4 or ENL (corresponding to t[4;11] and t[11;19], respectively). Their effect on hematological delished with cells carrying the Mll-AF9 fusion gene only developed hematological tumors, even though the use velopment and tumor phenotype could be assessed. In addition, it is likely that a similar methodology could of the AT-lac targeted fusion allowed the demonstration of Mll promoter activity in a wide variety of locations be applied to other gene fusions commonly found in hematological tumors, e.g., the BCR-ABL gene in myduring mouse development and in adult tissues ( Figures  2 and 3) . elogenous leukemia or fusions in solid tumors, such as the sarcomas, which also have consistent chromosomal
Our results provide formal proof that Mll-AF9 is important for hematological malignancy and, by creating a translocations (Rabbitts, 1994) .
recapitulation of the effect of chromosomal translocation, provide formal proof that chromosomal translocaThe Mll-AF9 Fusion Gene Causes Acute Leukemia The MLL gene on human chromosome 11, band q23, is tions are important in tumor development. Understanding the role of AF9 in derivation of the tumor type will involved with a remarkably large number of chromosomal translocations and inversions (reviewed by Bernecessitate a number of other comparisons, for example with the effect of MLL-AF4. However, it is very important nard and Berger, 1995) , and the site of breakage is rather consistent on the derivative 11q chromosome, which is to note that the Mll-AF9 fusion gene discussed here is present, and presumably expressed, in hematopoietic considered important for tumor development (Rowley, 1992) . Various fusion partners can be linked to the MLL stem cells. Thus, the specificity of tumors from the myeloid lineage suggests that the MLL-AF9 fusion protein gene after the formation of abnormal chromosomes (Bernard and Berger, 1995) , but the role of the incoming is predominantly oncogenic in myeloid or myeloid-committed cells. It is therefore conceivable that MLL translofusion partner is not clear at present.
A number of conclusions about the MLL fusions can cations could occur in other hematopoietic cells that thereby generated were estimated by agouti coat color compared remain normal. Nonetheless, lymphoid tumors are with the black color of the recipient strain.
known in humans that carry t(9;11) and thus the MLL-AF9 fusion. In view of our data, it is difficult to explain Mouse Analysis such tumors unless the incidence of lymphoid tumors GPI enzyme isozyme analysis was performed on blood or tissue is low in the chimeric mice and would only be detected samples as described previously (Papaioannou and Johnson, 1993) . may combine to determine lineage of the tumor.
Single cell suspensions in PBS containing 2% fetal calf serum were
In view of the long latency of tumor development in loaded with CMFDG after hypotonic shock for 2 min by addition of 0.2 mM CMFDG in water. The surface markers B220, CD3, CD4, the Mll-AF9 chimeric mice, it seems probable that secand CD8 were detected using antibodies directly coupled to phyondary mutations in other oncogenes are necessary for coerythrin (Pharmingen).
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